Brought to you by 
Navamedic to sell Orexigen's Mysimba in Scandinavia
09 Aug 2017
Executive Summary
Orexigen Therapeutics Inc. licensed Navamedic ASA rights to commercialize and distribute the obesity drug Mysimba (naltrexone HCl/bupropion HCl prolonged release) in Denmark, Finland, Iceland, Norway, and Sweden.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Navamedic to sell Orexigen's Mysimba in Scandinavia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice